Divisadero Street Capital Management LP Invests $4.71 Million in AngioDynamics, Inc. (NASDAQ:ANGO)

Divisadero Street Capital Management LP purchased a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 514,635 shares of the medical instruments supplier's stock, valued at approximately $4,714,000. Divisadero Street Capital Management LP owned approximately 1.27% of AngioDynamics at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. SBI Securities Co. Ltd. acquired a new stake in AngioDynamics during the 4th quarter worth approximately $28,000. R Squared Ltd acquired a new stake in shares of AngioDynamics during the fourth quarter worth $49,000. US Bancorp DE lifted its position in AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock valued at $61,000 after acquiring an additional 6,376 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in AngioDynamics in the 4th quarter worth $92,000. Finally, OneDigital Investment Advisors LLC increased its holdings in AngioDynamics by 14.0% during the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 1,490 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Stock Down 1.8 %

Shares of ANGO stock traded down $0.17 during trading on Friday, reaching $9.11. The company's stock had a trading volume of 278,516 shares, compared to its average volume of 556,947. AngioDynamics, Inc. has a one year low of $5.47 and a one year high of $13.50. The business has a fifty day moving average price of $9.42 and a 200-day moving average price of $9.30. The company has a market cap of $369.93 million, a price-to-earnings ratio of -1.62 and a beta of 0.58.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics's quarterly revenue was down 4.3% on a year-over-year basis. Research analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.